Advancing a pipeline in autoimmunity and oncology

While our initial programs are focused on autoimmunity and oncology, we are continuing to develop proprietary computational methods, drug designs of greater complexity and additional mechanisms of action.

Autoimmunuity

Targeted agonist delivery synergistically modulates regulatory T-cell activity in autoimmune disease.

Oncology

Precise tunability allows us to engineer therapeutic candidates that avoid systemic toxicity for improved safety profiles.

Partnerships

In addition to advancing our own innovative pipeline, we also collaborate with leading pharmaceutical companies.

Pipelines

Investors

Partners

News and media

Stay up to date with our news, announcements, and featured stories.

Press

Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases

Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities